From the Division of Hematology /Medical Oncology. Seyyed-al Shohada Hospital, Isfahan University of Medical Sciences. Isfahan, Islamic Republic of Iran.
Abstract: (5427 Views)
Twenty-one patients with advanced breast cancer (7 premenopausal and 14
postmenopausal women) were treated with a combination of cyclophosphamide,
doxorubicin, and cisplatin (CAP). The median age of the patients was 43 years (range
36-61). This therapy was repeated every 3 weeks. Nine patients (group 1) received
CAP as primary therapy for metastatic breast cancer, and twelve patients (group 2)
received CAP as a second-line therapeutic agent. Of the 12 (57%) patients who
responded, six (29%) had complete response (CR). The median disease-free survival
(DFS) was 8 months. The response rate was highest for metastases in the pleura
(83%) and lymph nodes (81 %), followed by skin (64%), liver and breast (55%). The
overall response rate was higher in previously untreated patients than in those
previously treated (89% versus 33%, p
Type of Study:
Original Research |
Subject:
Oncology